483
MassBiologicsMassBiologics – FDA 483, Dec 18, 2025
Record Details
An FDA inspection of MassBiologics, a Gene Therapy Testing Lab in Boston, revealed a significant deficiency regarding written procedures. The firm failed to establish and follow written procedures for annual evaluations, including reviews of complaints, recalls, and investigations for each drug product. Specifically, quality indicator reports for Kebilidi manufacturing lacked proper documentation and visual representation of drug product batch release data trends.
- Person
View Company Profile
ID · 32cddc50-58d8-43da-866b-326888199b33
Other documents for MassBiologics
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.